News round-up by DDW’s Megan Thomas for 18-22 October
DDW’s Megan Thomas has selected five stories which highlight the opportunities in the drug discovery sector.
Two Mount Sinai cancer researchers will receive $4 million from the National Institutes of Health (NIH) Common Fund, which supports research by junior scientists around the United States. This will fund radiation oncology and CAR T cell cancer therapy research.
Collaborative Drug Discovery (CDD) has released a free, full featured, standalone software tool: CDD Visualization. It is a browser-based application that allows scientists to visualise data and generate publication-ready graphs and plots.
A team of medical and pharmaceutical experts has founded SynaptixBio, an Oxford-based research company working to develop the world’s first disease-modifying treatment for TUBB4a leukodystrophy, including H-ABC – a debilitating and potentially life-limiting condition. This is a sponsored research agreement with Children’s Hospital of Philadelphia (CHOP) in the US.
CN Bio has launched an oncology service which it says is in response to the global need to improve cancer drug discovery approval rates.
BioIVT has added advanced tissue, biofluid and cell search and e-commerce capabilities to its website, which is enabling customers to mine its biospecimen repository and related clinical database using artificial intelligence (AI) and machine learning (ML) applications to advance scientific knowledge of different diseases.